If youre losing less than a pound a week on average, despite diet and exercise, you may be a good candidate for Wegovy or another weight loss medication
For most healthy adults, the clinical trials at common doses do not demonstrate clear, proven harms, but the TMAO question remains an area of active research
Phase 3 Update: TRIUMPH-4 Results Preliminary data from the ongoing Phase 3 TRIUMPH-4 trial (68 weeks) shows higher numbers than Phase 2: 12mg dose: 28.7% average weight loss (~71 lbs / 32 kg) 9mg dose: 26.4% average weight loss (~64 lbs / 29 kg) Knee osteoarthritis pain: 76% reduction (significant quality-of-life improvement) Blood pressure: Average reduction of 14 mmHg Full Phase 3 results across the TRIUMPH program (obesity, diabetes, cardiovascular outcomes, kidney outcomes) are expected throughout 2026
Working adults and families concerned about weight management or prediabetes may also discuss these medications with their healthcare professionals to determine if they are appropriate for their specific needs and health goals
By integrating pathways such as methylation, detoxification, inflammation, and nutrient utilisation, it offers a clear roadmap for building resilience, preventing disease, and sustaining long-term wellness